FIG. 1A



AD-85481 (3mg/kg)
AD-126306 (3mg/kg)
AD-133362 (3mg/kg)
AD-126308 (3mg/kg)
AD-126307 (3mg/kg)
Single Dose (NHP)
AGT (% of Pretreatment)
150
100
50
0
0
50
100
Days Post-Dose

FIG. 1B




Comparison of AD-67327 and AD-85481
AD-67327 (0.3 mg/kg)
AD-67327 (1 mg/kg)
AD-67327 (3 mg/kg)
AD-85481 0.3mg/kg
AD-85481 1mg/kg
AD-85481 3mg/kg
AGT (% of Pretreatment)
150
100
50
0
0
50
100
Days Post-Dose

FIG. 1C


Comparison of AD-67327 and AD-85481
Repeat Dosing
AD-67327 (1 mg/kg q4w)
AD-85481 (1 mg/kg q4w)
AGT (% of Pretreatment)
150
100
50
0
0
50
100
Days Post-Dose




plasma AGT
pmol/ml
1500
1000
500
0
baseline
T= 4 weeks
*
*
*
*
Vehicle
Valsartan
AGT siRNA
Valsartan/AGT siRNA
Valsartan/captopril
Captopril

FIG. 2A

FIG. 2B


mmHg
0
-25
-50
-75
-100
0
7
14
21
28
T (days)
Vehicle
Valsartan (31 mg/kg/day)
AGT siRNA (10 mg/kg q2w)
Captopril (100 mg/kg/day)
Captopril/valsartan
Valsartan/AGT siRNA
*
#
$



Heart weight:Tibia Length Ratio
mg/mm
40
30
20
10
~ Normal
Vehicle
Valsartan
AGT siRNA
Captopril
Captopril/valsartan
Valsartan/AGT siRNA

FIG. 2C



ng Ang I /ml.hr
300
200
100
0
Vehicle
Valsartan
AGT siRNA
Valsartan/AGT siRNA
Captopril/valsartan
Captopril

FIG. 2D

FIG. 2E




FIG. 2F





FIG. 2G





Urinary AGT
ng/day
200
150
100
50
0
Vehicle
Valsartan
Captopril
Captopril + Valsartan
AGT siRNA
Valsartan + AGT siRNA
*

FIG. 3

FIG. 4A




FIG. 4B




FIG. 4C




FIG. 5A




FIG. 5B




FIG. 5C




FIG. 6A




FIG. 6B





FIG. 6C





baseline
T= 4 weeks
Urinary volume
mL/day
0
10
20
30
40
Vehicle
Valsartan
AGT siRNA
Valsartan/AGT siRNA
Captopril/valsartan
Captopril
*
*
*
*

FIG. 7



Impact of AGT Silencing
on Weight Gain in DIO Mice
DIO-PBS
DIO-AGT
Control-PBS
Control-AGT
Weight (g)
60
50
40
30
20
0
5
10
15
Weeks Post Study Start

FIG. 8A



Organ Weights in DIO Mice
12 weeks post study-start
DIO-PBS
DIO-AGT
Control-PBS
Control-AGT
Weight (g)
0
1
2
3
4
Liver
Adipose
Muscle
Organ

FIG. 8B

FIG. 9A




FIG. 9B





FIG. 9C






FIG. 10A




FIG. 10B




FIG. 11A

FIG. 11B

FIG. 11C